Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06893081 · ClinicalTrials.gov registry record · Phase 1
A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06893081 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 16 participants.
The verdict
NCT06893081, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The goal of this study is to learn what happens to MK-8527 in a healthy person's body over time when MK-8527 is given alone and with the medication CBZ.
Interventions
- DRUG MK-8527
- DRUG CBZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2025-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06893081
The ClinicalTrials.gov registry entry for NCT06893081 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MK-8527 is the first listed.
NCT06893081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06893081 about?
NCT06893081 is a clinical study titled "A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)". The goal of this study is to learn what happens to MK-8527 in a healthy person's body over time when MK-8527 is given alone and with the medication CBZ.
What is the current status of trial NCT06893081?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-04-28. Estimated completion is 2025-07-17.
What interventions are being tested in trial NCT06893081?
The interventions under investigation include: MK-8527 (DRUG), CBZ (DRUG).
Who is sponsoring clinical trial NCT06893081?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.